Omecamtiv Mecarbil
Heart Failure with Reduced Ejection Fraction (HFrEF)
Key Facts
Indication
Heart Failure with Reduced Ejection Fraction (HFrEF)
Phase
Phase 3
Status
Active
Company
About Cytokinetics
Cytokinetics' mission is to develop innovative medicines that improve the healthspan of patients suffering from cardiovascular and neuromuscular diseases characterized by compromised muscle function. Its key achievement is the 2025 FDA approval of MYQORZO (aficamten), a first-in-class cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy (oHCM), validating its decades-long focus on sarcomere biology. The company's strategy is to build a leading muscle-focused specialty biopharma business by commercializing aficamten across HCM subtypes, advancing late-stage candidates in heart failure, and leveraging its platform to develop treatments for neuromuscular conditions like ALS.
View full company profileTherapeutic Areas
Other Heart Failure with Reduced Ejection Fraction (HFrEF) Drugs
| Drug | Company | Phase |
|---|---|---|
| Barostim™ | CVRx | FDA Approved / PMA |
| ALLAY-HFrEF | Alleviant Medical | Pivotal Trial |
| Neucardin® | Zensun Sci & Tech | Phase 2/3 |
| Cardiac Contractility Modulation (CCM) Implant | Berlin Heals | Pre-clinical / Early Clinical |
| SRD001 (inferred) | Sardocor | Phase 1 |
| Undisclosed HFrEF Program | NanoPhoria Bioscience | Preclinical |
| AC01 | AnaCardio | Phase 2 |
| Firibastat | Quantum Genomics | Phase II |